3 results
The objectives are to evaluate the long-term safety and tolerability profile of aducanumab in subjects with early AD, and to evaluate the long-term efficacy of aducanumab treatment as measured by clinical, radiological and additional assessments…
Primary objective:To evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e., previously treated…
The primary objectives are to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RP2D) of ABBV-621 and to evaluate pharmacokinetics (PK) of (A) single agent ABBV-621; and (B) the combination of ABBV-621 and venetoclax in…